Defender Capital, Llc. Lineage Cell Therapeutics, Inc. Transaction History

Defender Capital, Llc.

$239 Million
Q1 2025

A detailed history of Defender Capital, Llc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Defender Capital, Llc. holds 6,310,873 shares of LCTX stock, worth $6.18 Million. This represents 1.19% of its overall portfolio holdings.

Number of Shares

6,310,873

Previous 5,963,348 5.83%

Holding current value

$6.18 Million

Previous $2.98 Million 4.76%

% of portfolio

1.19%

Previous 1.17%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 28, 2025	BUY	$0.45 - $0.72 $156,386 - $250,218	347,525 Added 5.83%	6,310,873 $2.84 Million
Q4 2024 Jan 23, 2025	BUY	$0.5 - $0.95 $480,575 - $913,092	961,150 Added 19.21%	5,963,348 $2.98 Million
Q3 2024 Oct 21, 2024	BUY	$0.8 - $1.12 $23,378 - $32,729	29,223 Added 0.59%	5,002,198 $4.55 Million
Q2 2024 Jul 29, 2024	BUY	$0.89 - $1.47 $4,717 - $7,791	5,300 Added 0.11%	4,972,975 $4.97 Million
Q1 2024 May 06, 2024	SELL	$0.86 - $1.48 $1,720 - $2,960	-2,000 Reduced 0.04%	4,967,675 $7.35 Million
Q4 2023 Jan 23, 2024	SELL	$0.91 - $1.35 $195,499 - $290,027	-214,835 Reduced 4.14%	4,969,675 $5.42 Million
Q3 2023 Oct 23, 2023	BUY	$1.16 - $1.53 $86,768 - $114,444	74,800 Added 1.46%	5,184,510 $6.12 Million
Q2 2023 Jul 18, 2023	SELL	$1.26 - $1.53 $33,232 - $40,353	-26,375 Reduced 0.51%	5,109,710 $7.2 Million
Q1 2023 Apr 27, 2023	BUY	$1.2 - $1.53 $51,060 - $65,101	42,550 Added 0.84%	5,136,085 $7.7 Million
Q4 2022 May 16, 2023	SELL	$1.02 - $1.5 $43,401 - $63,825	-42,550 Reduced 0.83%	5,093,535 $5.96 Million
Q4 2022 Jan 12, 2023	SELL	$1.02 - $1.5 $92,310 - $135,750	-90,500 Reduced 1.75%	5,093,535 $5.96 Million
Q3 2022 Oct 18, 2022	BUY	$1.13 - $1.77 $58,872 - $92,217	52,100 Added 1.02%	5,184,035 $5.86 Million
Q2 2022 Jul 26, 2022	BUY	$1.12 - $1.61 $140,840 - $202,457	125,750 Added 2.51%	5,131,935 $8.11 Million
Q1 2022 Apr 22, 2022	BUY	$1.21 - $2.48 $10,061 - $20,621	8,315 Added 0.17%	5,006,185 $7.98 Million
Q4 2021 Feb 01, 2022	BUY	$1.84 - $2.68 $367,264 - $534,928	199,600 Added 4.16%	4,997,870 $12.2 Million
Q3 2021 Nov 01, 2021	SELL	$2.26 - $2.86 $538,897 - $681,967	-238,450 Reduced 4.73%	4,798,270 $12.7 Million
Q2 2021 Jul 29, 2021	BUY	$2.17 - $3.0 $186,620 - $258,000	86,000 Added 1.74%	5,036,720 $14.4 Million
Q1 2021 Apr 20, 2021	BUY	$1.77 - $3.1 $380,072 - $665,663	214,730 Added 4.53%	4,950,720 $11.6 Million
Q4 2020 Jan 25, 2021	SELL	$0.95 - $1.83 $297,350 - $572,790	-313,000 Reduced 6.2%	4,735,990 $8.34 Million
Q3 2020 Oct 23, 2020	BUY	$0.75 - $1.09 $302,025 - $438,943	402,700 Added 8.67%	5,048,990 $4.73 Million
Q2 2020 Jul 10, 2020	BUY	$0.71 - $1.18 $163,087 - $271,046	229,700 Added 5.2%	4,646,290 $4.04 Million
Q1 2020 May 14, 2020	BUY	$0.6 - $1.58 $263,727 - $694,481	439,545 Added 11.05%	4,416,590 $3.66 Million
Q4 2019 Feb 03, 2020	BUY	$0.54 - $1.01 $98,820 - $184,830	183,000 Added 4.82%	3,977,045 $3.54 Million
Q3 2019 Oct 17, 2019	BUY	$0.85 - $1.24 $3.22 Million - $4.7 Million	3,794,045 New	3,794,045 $3.71 Million

Others Institutions Holding LCTX

# of Institutions

138

Shares Held

108M

Call Options Held

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $166M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Defender Capital, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Defender Capital, Llc. with notifications on news.

Account

Defender Capital, Llc. Lineage Cell Therapeutics, Inc. Transaction History